AnHorn Medicines has dosed the first subject in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN).

This milestone marks the clinical advancement of a novel therapeutic approach designed to address one of the most common and debilitating complications of cancer treatment.

CIPN is a frequent and dose-limiting side effect of widely used cancer therapies, including taxanes, platinum-based agents, vinca alkaloids, and antibody-drug conjugates (ADCs). CIPN can cause numbness, tingling, pain, and sensory impairment that often persist long after treatment ends.

Studies indicate that 60–70% of patients experience CIPN during or shortly after chemotherapy, and nearly one-third continue to suffer six months or longer post-treatment. Despite its substantial burden, no approved therapies currently exist to prevent CIPN, and treatment options for established neuropathy remain limited1.

Preventing CIPN

CIPN not only impacts patient quality of life but also forces oncologists to reduce chemotherapy doses, delay schedules, or discontinue therapy—compromising treatment outcomes.

By preventing nerve damage before it occurs, AH-008 has the potential to:

  • Improve quality of life for patients undergoing chemotherapy
  • Reduce treatment-related pain, numbness, and sensory dysfunction
  • Preserve chemotherapy dose intensity and adherence
  • Enable patients to remain on optimal anti-cancer regimens
  • Reduce long-term healthcare costs associated with chronic neuropathy

“The economic burden of CIPN is estimated at approximately $17,000 per patient, translating into a total societal burden of up to $153 billion. Preventing CIPN represents one of the most significant unmet needs in supportive oncology today,” said Shu-Jen Chen, Chief Scientific Officer of AnHorn Medicines. “The successful first patient dosing in our Phase I study marks an important step toward developing a disease-modifying therapy that could protect patients from debilitating nerve damage while enabling them to receive the full benefit of cancer treatment.”

Market opportunity

Each year, millions of cancer patients worldwide receive neurotoxic chemotherapy agents associated with CIPN. As these regimens expand across global markets, CIPN remains one of the most common and clinically meaningful dose-limiting toxicities in oncology.

With no approved preventive therapies, the global addressable market for CIPN prevention is estimated at US$15-19 billion annually, underscoring the significant commercial opportunity for a first-in-class approach2.

The treatment-enabling paradigm of AH-008 is analogous to granulocyte colony-stimulating factors (G-CSF), such as Neulasta, which prevent chemotherapy-induced neutropenia and enable full-dose chemotherapy. Similarly, AH-008 may establish a new standard of care in supportive oncology by addressing a key toxicity that currently limits cancer treatment delivery.

References

  1. Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155(12):2461-2470.
  2. Company calculation based on the size of chemotherapy new incidence patients per year in 16 major pharmaceutical markets.